Observational studyAnnals of hematology2024

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.

Aleksander Chojecki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.